Opus ARVO Data Show Early Promise, But CMC Gate Remains the Real Catalyst

What happened

At ARVO 2026, Opus reported six-month LCA5 data showing cone-mediated vision restoration in pediatric patients, with sensitivity reaching normal ranges, and early BEST1 data with visual acuity gains and improved retinal structure. Preclinical RHO and mutation-independent AAV programs also progressed, supporting pipeline breadth. Despite these positive clinical signals, the pivotal LCA5 program remains gated by validated commercial-process drug supply, a manufacturing hurdle that the press release does not address. Early BEST1 data supports expansion into a larger IRD population but is still small-n and early. Overall, the data de-risks clinical assets moderately but does not alter the near-term dependency on CMC execution and controlled cash burn.

Implication

If CMC validation for LCA5 succeeds and operating cash use stays near $25M/9M run-rate, the positive clinical data increases the probability of bull case ($5.20). However, any manufacturing delay will reinforce the bear case ($1.80) by extending dilution and weakening catalyst credibility. Maintain position sizing that assumes dilution until auditable CMC progress is disclosed.

Thesis delta

The ARVO data incrementally improves the probability of clinical success for LCA5 and BEST1, but the core thesis remains unchanged: the next 6-12 months are dominated by the CMC validation gate for LCA5 and cash burn trajectory. Positive data reduces some binary clinical risk, but manufacturing execution is the binding constraint. The WAIT rating is maintained with a slightly higher conviction in asset quality, but the price still offers no margin of safety against the dilution risk embedded in the CMC timeline.